1. BrennanZ.Biosimilars in the EU: lower costs, increased patient access, IMS report finds. Available at: http://raps.org/Regulatory-Focus/News/2016/06/20/25166/Biosimilars-in-the-EU-Lower-Costs-Increased-Patient-Access-IMS-Report-Finds/. Accessed August 2016.
2. BrennanZ.IMS: biosimilars could save up to $110B in EU, US through 2020. Regulatory Affairs Professionals Society (RAPS). Available at: http://www.raps.org/Regulatory-Focus/News/2016/03/29/24671/IMS-Biosimilars-Could-Save-Up-to-110B-in-EU-US-Through-2020/. Accessed June 30, 2016.
3. Hot topics in primary care: demystifying the differences: follow-on biologics, biosimilars, and generics;Wright;J Fam Pract,2017
4. Developing the nation's biosimilars program;Kozlowski;N Engl J Med,2011